Antibiotic Incentive Legislation: Can Reimbursement Horn In?
This article was originally published in RPM Report
There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.
You may also be interested in...
Anti-infective drug development companies appear set to receive another round of legislative incentives as the “Cures” process moves forward. The only question is when and how much they will receive. One provision—creating a new limited use pathway—could be important for all classes of drug development.
The 2012 FDA Safety & Innovation Act included important new incentives for antibiotic developers. But the Obama Administration and key legislators want to do even more to revive R&D in the space. What will it take to bring Big Pharma back?
Goal of 10 new antibiotics by 2020 may be unlikely given current marketplace for antibiotics, some experts predict as a new study shows recent proposals to revive development may be focused at wrong point in development timeline. Study suggests need for large increases in government funding.